Methods of enhancing T cell responsiveness

• US 7,794,710 B2
• Filed: 04/22/2002
• Issued: 09/14/2010
• Est. Priority Date: 04/20/2001
• Status: Expired due to Term

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Chen, Lieping, Strome, Scott E.
• Primary Examiner(s): OUSPENSKI, ILIA I
• Application Number:
  US10/127,282
• Publication Number:
  US 20030039653A1
• Time in Patent Office: 3,067 Days
• Field of Search: 424/130.1, 424/141.1, 424/144.1, 424/154.1, 530/387.1, 530/388.1, 530/388.22, 530/388.75, 435/375
• US Class Current: 424/130.1
• CPC Class Codes: A61K 2039/515 Animal cells
• CPC Class Codes: A61K 2239/31 characterized by the route of administration
• CPC Class Codes: A61K 2239/38 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/4632 T-cell receptors [TCR]; antibody T-cell receptor constructs
• CPC Class Codes: A61K 39/4644 Cancer antigens
• CPC Class Codes: A61K 39/464411 Immunoglobulin superfamily
• CPC Class Codes: A61K 39/464486 MAGE
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12N 2501/23 Interleukins [IL]
• CPC Class Codes: C12N 2501/51 B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
• CPC Class Codes: C12N 5/0636 T lymphocytes

Abstract

The invention features methods of enhancing the responsiveness of a T cell. Such methods involve interfering with the interaction between a T cell and a B7-H1 molecule.

Claims

1. A method of inhibiting tumor cell proliferation in a subject, comprising:

(a) identifying a subject with cancer; and

(b) administering to the subject an antibody that binds to B7-H1.

2. The method according to claim 1, wherein cells of the cancer are identified as expressing B7-H1 molecules on their surfaces.

3. The method according to claim 1, wherein said B7-H1 comprises the amino acid sequence set forth in SEQ ID NO:

3.

4. The method according to claim 1, wherein said antibody interferes with an interaction between the T cell and B7-H1.

5. The method according to claim 1, wherein said subject is a human.

6. The method according to claim 1, wherein said subject is a mouse.

7. The method of claim 1, wherein the cancer is a hematological cancer, a neurological cancer, breast cancer, a gastrointestinal cancer, or a genitourinary cancer.

8. The method of claim 7, wherein the gastrointestinal cancer is colon cancer.

9. The method of claim 7, wherein the genitourinary cancer is ovarian cancer.

10. The method of claim 1, wherein the cancer is melanoma.

11. The method of claim 1, wherein the cancer is lung cancer.

12. The method of claim 1, wherein the cancer is head and neck cancer, liver cancer, pancreatic cancer, bone cancer, or a vascular cancer.

13. The method of claim 1, wherein the antibody is a monoclonal antibody.

14. The method of claim 1, wherein the antibody is a polyclonal antibody.

15. The method of claim 1, wherein the antibody is an antigen-binding fragment.

16. The method of claim 15, wherein the antigen-binding fragment is a single chain Fv fragment.

17. The method of claim 1, wherein the antibody is a chimeric antibody.

18. The method of claim 1, further comprising delivering one or more cytokines to the subject.

19. The method of claim 1, further comprising administering an immunogenic stimulus to the subject.

20. The method of claim 19, wherein the immunogenic stimulus comprises a tumor-associated antigen.